Gemayel Georges
SEC-identified person · CIK 1256088 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Gemini Therapeutics, Inc. /DE IRON | Director · See Remarks | filed 2021–2026 |
| Supernus Pharmaceuticals, INC. SUPN | Director | filed 2015–2026 |
| Momenta Pharmaceuticals INC MNTA | Director | filed 2016–2020 |
| Dimension Therapeutics, Inc. DMTX | Director | filed 2015–2017 |
| Torreypines Therapeutics, Inc. TPTX | Director | filed 2015–2016 |
| NPS Pharmaceuticals INC NSPS | Director | filed 2012–2015 |
| Adolor Corp adlr | Director | filed 2007–2011 |
| Altus Pharmaceuticals Inc. ALTU | Director · President & CEO | filed 2008–2009 |
| Genzyme Corp u4yfvwk$ | Executive Vice President | filed 2006–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.